The post-viral problem
Millions of patients worldwide continue to experience debilitating symptoms months or years after viral infection. Fatigue, cognitive impairment, cardiovascular instability, and chronic pain persist despite conventional treatment.
Emerging research points to three interconnected mechanisms: persistent immune activation with elevated autoantibodies, microclot formation impairing capillary blood flow, and ongoing endothelial inflammation. Standard pharmaceutical approaches address symptoms but often fail to resolve the underlying pathology.
How apheresis intervenes
Immunoadsorption selectively removes the autoantibodies driving immune dysregulation. Plasmapheresis clears inflammatory mediators and microclots from circulation. INUSpheresis targets residual toxins and inflammatory debris. The combination of modalities is tailored to the individual patient’s diagnostic profile.
Clinical outcomes
Patients undergoing targeted apheresis protocols report significant improvements in fatigue, cognitive clarity, exercise tolerance, and pain levels. Objective measures including inflammatory markers, fibrinogen levels, and D-dimer typically improve in parallel with subjective symptom relief.
When the blood is clean, the body can heal.
At Elysium, post-viral patients receive a dedicated diagnostic workup before treatment begins. The protocol is adjusted based on laboratory response at each stage.
